From Stockholm, Sweden, a 2008 piece titled “Teratogenic effects of antiepileptic drugs.” and appearing in the medical journal, Seizure, by T. Tomson et al. yet again demonstrates the postnatal risks of prenatal exposure to epilepsy drugs containing sodium valproate such as Depakote, Depakene, and Depacon (Abbott Laboratories, Inc.).

Here, it is stated that “The use of older generation antiepileptic drugs (AEDs) during pregnancy is known to be associated with a two- to threefold increased risk of birth defects in the offspring and possible also other adverse outcomes in the exposed infant”, warning that “Much less has been known about newer generation AEDs in this respect.”  To be clear, valproate is considered “second-” or “newer-generation.”

Because “Recent studies based on national registries as well as specific epilepsy and pregnancy registries are beginning to provide information on comparative teratogenic effects of different AEDs”, the team purports that “the prevalence of birth defects appears to be higher with exposure to valproate compared with carbamazepine and possibly also in comparison with lamotrigine.” (emphasis added)

And, states Tomson, “Retrospective and a few small prospective studies suggest that exposure to valproate also might be associated with a lower verbal IQ at school age”, calling for further research.

Because these drugs have been known by the medical community to cause birth defects for so long, Depakote birth defect lawsuits have been filed in great number across the country and around the world.  If you or a loved one used Depacon, Depakote, or Depakene when pregnant and your child was born with a congenital malformation, your family may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the compassion, resources, and experience required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

In recent years, a number of studies have shown that prenatal exposure to sodium valproate (the active ingredient in epilepsy drugs Depacon, Depakene, and Depakote) is linked to increased risk for birth defects.  Here, I’ll summarize one such study, titled “Differential effects of antiepileptic drugs on neonatal outcomes.” by P.B. Pennell and a team from Harvard Medical School that originally appeared in the August, 2012 edition of Epilepsy and Behavior.

Pennell states, “Offspring of women with epilepsy (WWE) on AEDs are at increased risks for major congenital malformations and reduced cognition”, and “They may be at risk for other adverse neonatal outcomes.”

For this study, “Women with epilepsy on carbamazepine (CBZ), lamotrigine (LTG), phenytoin (PHT), or valproate (VPA) monotherapy were enrolled in a prospective, observational, multicenter study of the neurodevelopmental effects of AEDs.”

Results showed that the risk for “small for gestational age (SGA) was higher for VPA vs. PHT, VPA vs. LTG, and CBZ vs. PHT”, meaning that Depakote (etc.) was linked to birth defects.

The team also found that “Microcephaly rates were elevated to 12% for all newborns and at 12 months old, but normalized by age 24 months” and “Reduced Apgar scores occurred more frequently in the VPA and PHT groups at 1 min, but scores were near normal in all groups at 5 min.” (emphasis added)  To be clear, Apgar score is a measure of neonatal adaptation wherein higher scores indicate better adaptation.

As such, these researchers concluded that “This study demonstrates increased risks for being born SGA in the VPA and CBZ groups, and transiently reduced Apgar scores in the VPA and PHT groups.”

Because so many women used Depacon in pregnancy unaware of the risks for birth defects, Depacon birth defect lawsuits have been filed in great number across the country.  If you or a loved one used Depacon, Depakote, or Depakene during pregnancy and your child was born with a congenital malformation or had perinatal complications, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

Titled “Malformation in infants of mothers with epilepsy receiving antiepileptic drugs.”, a piece of Japanese medical research by S. Kaneko et al. published in April, 1992 helps show just how long it has been known that prenatal exposure to epilepsy drugs containing valproate is linked to birth defects.  Depacon, Depakote, and Depakene are top examples of these drugs and are manufactured by Abbott Laboratories, Inc.

Aiming “To assess the relative contribution of antiepileptic drugs (AEDS) to occurrence of congenital malformations, [this research team] compared two prospective studies” and “analyzed data for 14 AEDs for total daily doses (drug score) and eight background factors.”

“From the first study, the drug score and polytherapy–particularly the use of valproate plus carbamazepine–were suspected to be primary factors for increased incidence of congenital malformation. In the other study, the drug score for each case was decreased, and polytherapy–particularly valproate plus carbamazepine–was changed to monotherapy before conception. These changes significantly decreased the incidence of malformations.”  This means valproate contributed to birth defects more than the other drug.

The team writes that “When data were corrected for seizure type, maternal age at delivery, or etiology of epilepsy, the difference in the incidence of malformations did not disappear, but it did disappear when data were corrected for drug score or number of AEDs. These results support our previous observations that AEDs are primary factors for the increased incidence of congenital malformation in infants of mothers with epilepsy.”

Due to the fact that Abbott and other epilepsy drug manufacturers have failed to warn women of these risks, even though it is clearly demonstrable that the companies knew, or should have known the risks, Depacon birth defect lawsuits are currently being filed around the world.

If you or a loved one used Depacon, Depakote, or Depakene while pregnant and your child was born with a birth defect or perinatal complications, your family may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the compassion, experience, and resources required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

In May, 2013, a Finnish team of medical researchers led by M. Aratma published a study in Drug Safety titled “Effects of maternal epilepsy and antiepileptic drug use during pregnancy on perinatal health in offspring: nationwide, retrospective cohort study in Finland.”.  This piece further elucidated the link between prenatal exposure to antiepileptic drugs such as Depacon, Depakene, and Depakote and serious birth defects.

Noting that “Antiepileptic drugs (AEDs) pass through the placenta and may affect neonatal outcome”, the team performed a “register-based study … based on information on all pregnancies ending in birth in Finland between 1996 and 2008” and included 751,139 singleton births in all.

After statistical analysis, Aratma found that “4,867 (0.6 %) infants (including live births and stillbirths) were exposed to maternal epilepsy. More than half of the offspring of WWE were exposed to AED (n = 3,067, 63.0 %) during pregnancy or 1 month prior to and/or during pregnancy, and mostly in monotherapy (n = 2,566, 83.7 %).”

And, “A slightly increased risk for most of the perinatal health outcomes was found in offspring of WWE in relation to offspring of WOE (adjusted odds ratio [aOR] 1.19, 95 % CI 1.04-1.36 for low 5-min Apgar score to aOR 2.10, 95 % CI 1.57-2.81 for needing respiratory care). The risks increased by the number of different maternal AEDs used. In relation to offspring of WWE with no AED exposure (n = 1,800), a slightly increased risk for treatment in a neonatal care unit (aOR 1.48, 95 % CI 1.21-1.82) was observed for offspring of WWE on AED therapy.”

This means that “Offspring of WWE have a slightly increased risk for adverse pregnancy-related and perinatal health outcomes when compared with WOE, and AED exposure further increases the risk.”

Due to the fact that the manufacturers of many AEDs have failed to warn women of these risks linked to AED use in pregnancy, Depakote birth defect lawsuits have been filed in great number in recent years.

If you or a loved one used AEDs like Depacon, Depakote, or Depakene during pregnancy and your child was born with a birth defect, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

In a 2003 edition of Epilepsia, a piece titled “Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation.” by M.S. Yerby and a team from North Pacific Epilepsy Research in Portland, Oregon demonstrated that a child’s in utero exposure to maternal antiepileptic drugs (particularly those containing valproate – Depakote, Depakene, Depacon; Abbott Laboratories, Inc.) is linked to a range of serious birth defects.

The team states, “Women with epilepsy (WWE) have a risk of bearing children with congenital malformations that is approximately twice that of the general population. Most antiepileptic drugs (AEDs) have been associated with such risk. Valproate and carbamazepine have been associated specifically with the development of neural tube defects (NTDs), especially spina bifida.” (emphasis added).

Because Abbott Laboratories, a major manufacturer of drugs containing valproate has failed time and again to adequately warn women of these and other serious risks, Depacon birth defect lawsuits are currently being filed in great number.

If you or a loved one used Depacon, Depakote, or Depakene during pregnancy and your child was born with a congenital malformation such as spina bifida, your family may be entitled to significant financial compensation from the manufacturer.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

A piece by medical researchers led by F.J. Vajda published in Acta Neurol Scand. (October, 2013), titled “Associations between particular types of fetal malformation and antiepileptic drug exposure in utero.” lives up to its title and provides more insight into the link between in utero exposure to epilepsy medication (Depacon, Depakene, and Depakote by Abbott Laboratories, Inc.) and birth defects.  To be clear, valproate is the active chemical in the drugs listed above.

Aiming to “study associations between patterns of fetal malformation and individual antiepileptic drugs taken during pregnancy”, this team analyzed data “relating to 1733 fetuses from 1703 pregnancies (147 of which were not exposed to antiepileptic drugs during pregnancy).”

Results showed that “There were statistically significant (P < 0.05) associations between (i) valproate exposure and spina bifida, malformations of the heart and great vessels, digits, skull bones, and brain, but not hypospadias, cleft palate/lip and mouth abnormalities, (ii) topiramate exposure and hypospadias and brain maldevelopments, and (iii) carbamazepine (CBZ) exposure and renal tract abnormalities.”

“The valproate findings are mostly in keeping with the published literature, but the topiramate finding regarding hypospadias and the association between CBZ exposure and various renal tract abnormalities raise questions of organ specific teratogenesis. More extensive data are desirable, particularly in relation to topiramate, which is being used increasingly as a migraine prophylactic in women of childbearing potential.”

Because this research linked such a wide range of serious birth defects with Depakote, Depakene, and Depacon exposure, this article can be used in a Depacon birth defect lawsuit.  If you or a loved one used Depacon, Depakote, or Depakene during pregnancy and your child was born with a congenital malformation, your family may be entitled to significant financial compensation from Abbott Laboratories.

For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

Appearing in the July-August, 2009 edition of the Spanish medical journal, Neurologia, a piece titled “Malformations and fetal death in the Spanish antiepileptic drug and pregnancy registry: results at 6 years” by M. Martinez Ferri et al. aimed to “study the incidence of major congenital malformations (MCM) /and/or fetal-perinatal death (MFP) and determine his relationship to AEDs in the Spanish EURAP registry.”  Over the last two decades, dozens of studies have shown that prenatal exposure to antiepileptic drugs containing sodium valproate (the active ingredient in Depacon, Depakene, and Depakote) is linked to increased risk for a range of serious birth defects.

In this study, “After informed consent, patients were included in the prospective Registry and evaluated: at the beginning, at the end of the second and third trimester, after delivery and one year after birth. A variety of variables were collected: demographic, type of epilepsy, frequency of seizures during pregnancy, AEDs and dose, potential toxics, folate use and dose, obstetric complications and information of the newborn. After 6 years of recruitment (June 2001-October 2007) we analyzed the results of this Registry in Spain with special attention on the incidence of major congenital malformations and foetal-perinatal death.”

The team states “Of a whole of 540 cases included in the Registry, 490 were prospective (included before the 16th week), of these we had complete information in 368 cases. Major congenital maLformations were present in 5% (n=13) of the child exposed to monotherapy and 12% (n=6) of those exposed to polytherapy (p=0.08). All polytherapy combinations with MCM, contained valproate.”

“The percentage of MCM was superior for valproate, particularly at doses equal or superior of 1000 mg/day (16%), although differences were not statistically significant. The majority of ours patients were on monotherapy (83%) with AEDs at low doses and were taking 5 mg of folate.”

Concluding that “Patients on polytherapy, particularly those with valproate in combination present more risk of MCM”, “For monotherapy exposures only weight at birth and the AEDs used have association statistically significant with MC/MFP”, and “Valproate in our series presents more risk than lamotrigine and does not show differences with regard to carbamazepine”, this article can be used in a Depacon birth defect lawsuit to demonstrate to a court that the manufacturers of these drugs knew, or should have known the risks of Depacon and failed to act.

If you or a loved one used Depacon, Depakote, or Depakene in pregnancy and your child was born with a birth defect, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the compassion, experience, and resources required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

In April, 2002, a team of medical researchers from Aberdeen (UK) led by J.C. Dean published a study titled “Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth.” in Journal of Medical Genetics investigating the link between neonatal and later childhood morbidity “in children exposed to antiepileptic drugs [AEDs] in utero.”  To-date, many studies have demonstrated that prenatal exposure to AEDs like Depacon, Depakene, and Depakote is linked to an increased risk for birth defects.

The team states “Mothers taking antiepileptic drugs in pregnancy between 1976 and 2000 were ascertained from hospital obstetric records and 149 (58% of those eligible) took part. They had 293 children whose health and neurodevelopment were assessed.”

After standard statistical analyses, “Neonatal withdrawal was seen in 20% of those exposed to antiepileptic drugs. Congenital malformations occurred in 14% of exposed pregnancies, compared with 5% of non-exposed sibs, and developmental delay in 24% of exposed children, compared with 11% of non-exposed sibs.”  This shows a dramatically increased risk for birth defects, developmental delay, and neonatal withdrawal for children exposed to AEDs in utero.

Dean et al. (2002) also write that “After excluding cases with a family history of developmental delay, 19% of exposed children and 3% of non-exposed sibs had developmental delay, 31% of exposed children had either major malformations or developmental delay, 52% of exposed children had facial dysmorphism compared with 25% of those not exposed, 31% of exposed children had childhood medical problems (13% of non-exposed sibs), and 20% had behaviour disorders (5% of non-exposed).” (emphasis added)

Concluding that “Prenatal antiepileptic drug exposure in the setting of maternal epilepsy is associated with developmental delay and later childhood morbidity in addition to congenital malformation”, this study can be used as evidence in a Depacon birth defect lawsuit to demonstrate that AED manufacturers knew, or should have known that their products are linked to birth defects.  Because these manufacturers failed to notify women of these risks, if you or a loved one used Depacon, Depakote, or Depakene during pregnancy and your child was born with a congenital malformation or had perinatal complications, you may be entitled to significant financial compensation.

For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

An article appearing in the May, 2010 edition of Epilepsia titled “The teratogenic risk of antiepileptic drug polytherapy.” by F.J. Vajda and a team from Royal Melbourne Hospital and University of  Melbourne (Australia) further explores the connection between antiepileptic drugs containing sodium valproate such as Depacon, Depakene, and Depakote and increased risk for congenital malformations.

For this study the team performed a “Statistical analysis of malformation rate and antiepileptic drug exposure data from the Australian Register of Antiepileptic Drugs in Pregnancy, and from [medical] literature.”

Results showed that “The calculated relative risk (RR) value for AED polytherapy compared with monotherapy was below 1.0 in only 3 of 14 literature publications. In the register, at 1 year postnatally there were fetal malformations in 5.32% of 282 AED polytherapy pregnancies, and in 7.84% of 791 AED monotherapy pregnancies, an RR of 0.68 [95% confidence interval (CI) 0.39-1.17). For pregnancies exposed to valproate, the RR of fetal malformation (0.39, 95% CI 0.20-0.89) was lower in polytherapy (7.26%) than in monotherapy (17.9%); the difference did not depend on valproate dosage. The RR values for fetal malformation were not significantly different for AED polytherapy and monotherapy when valproate was not involved. Logistic regression suggested that coadministration of lamotrigine may have reduced the malformation risk from valproate.”

What all this means is that exposure to drugs containing valproate increased risk for birth defects compared to other antiepileptic treatments.  As such, the team concluded that patients should add the drug lamotrigine and not use only valproate during pregnancy.

Because the manufacturer of these drugs, Abbott Laboratories, has failed time and again to warn women of these and other serious risks linked to prenatal valproate exposure, Depacon birth defect lawsuits are currently being filed around the world.

If you or a loved one used Depacon, Depakote, or Depakene during pregnancy and your child was born with a congenital malformation or had perinatal complications, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.

In February, 2011, C. Nadebaum and a British research team published a piece in Neurology titled “Language skills of school-aged children prenatally exposed to antiepileptic drugs.” that provides important insight into the connection between antiepileptic drugs containing sodium valproate (Depacon, Depakene, and Depakote) and birth defects.

Nadebaum et al. (2011) state “Fetal exposure to some antiepileptic drugs (AEDs) carries increased risk of major birth defects, and may be associated with reduced intellectual abilities. The impact on language remains unclear. This study aimed to investigate the impact of fetal AED exposure on language skills.”

Studying language skills of “102 AED-exposed children” and comparing results to a control group, the team found that “Mean CELF-4 Core Language scores of children exposed to sodium valproate in monotherapy (mean 91.5, SD 17.5) or polytherapy (mean 73.4, SD = 22.3) were significantly below the standardized test mean of 100 (p < 0.05).”  This means that babies with Depacon exposure had significantly lower language skill later in life.

The team also found that babies exposed to several other antiepileptic drugs had normal language skills.  And, “First-trimester sodium valproate dose was negatively correlated with language scores, and significantly predicted language scores after controlling for other group differences.”

Because Abbott Laboratories, the company that makes Depacon, Depakene, and Depakote, has failed to warn women of the risk for birth defects, Depacon birth defect lawsuits have been filed in great number over the last several years.

If you or a loved one used Depacon, Depakote, or Depakene during pregnancy and your child was born with a birth defect, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Depacon birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5528

justinian@dangerousdrugs.us

Our Depacon Lawsuit Information page is a great place to start if you have any questions about Depacon.